home / stock / vtgn / vtgn news

VTGN News and Press, VistaGen Therapeutics Inc. From 02/26/19

Stock Information
Company Name: VistaGen Therapeutics Inc.
Stock Symbol: VTGN
Market: NASDAQ
Website: vistagen.com
Menu
VTGN VTGN Quote VTGN Short VTGN News VTGN Articles VTGN Message Board
Get VTGN Alerts

News, Short Squeeze, Breakout and More Instantly...
VTGN - VistaGen Therapeutics Announces Pricing of Underwritten Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., Feb. 26, 2019 (GLOBE NEWSWIRE) -- VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for depression and other central nervous system (CNS) diseases and disorders with high unmet need, today anno...
VTGN - VistaGen Therapeutics Announces Proposed Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., Feb. 25, 2019 (GLOBE NEWSWIRE) -- VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for depression and other central nervous system (CNS) diseases and disorders with high unmet need, today announ...

VTGN - VistaGen Therapeutics Receives AV-101 Japanese Patent for Treatment of Depression and Hyperalgesia

SOUTH SAN FRANCISCO, Calif., Feb. 19, 2019 (GLOBE NEWSWIRE) -- VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for depression and other central nervous system (CNS) diseases and disorders with high unmet need, today an...

VTGN - VistaGen Therapeutics Receives Notice of Allowance for U.S. Patent for Treatment of Depression with PH10

SOUTH SAN FRANCISCO, Calif., Feb. 13, 2019 (GLOBE NEWSWIRE) -- VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for depression and other central nervous system (CNS) diseases and disorders with high unmet need, today an...
VTGN - VistaGen Therapeutics misses by $0.11

VistaGen Therapeutics (NASDAQ: VTGN ): Q3 GAAP EPS of -$0.24 misses by $0.11. More news on: VistaGen Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

VTGN - VistaGen Therapeutics Reports Fiscal 2019 Third Quarter Financial Results

SOUTH SAN FRANCISCO, Calif., Feb. 12, 2019 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc.  (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for treating depression and other central nervous system (CNS) diseases and disorders with high ...

VTGN - VistaGen Therapeutics to Present at the 21st Annual BIO CEO & Investor Conference on February 11, 2019

SOUTH SAN FRANCISCO, Calif., Feb. 05, 2019 (GLOBE NEWSWIRE) -- VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and disorders with high unmet need, today announced that Shawn Sing...
VTGN - VistaGen up 5% on preclinical AV-101 data

Thinly traded nano cap VistaGen Therapeutics ( VTGN +5.3% ) is up on double normal volume following its announcement of encouraging preclinical data on lead candidate AV-101 (4-chlorokynurenine), in development for major depressive disorder and neuropathic pain. More news on: VistaGen ...

VTGN - FB, GE, VLO among premarket gainers

Fortress Biotech (NASDAQ: FBIO ) +56%  on Caelum deal with Alexion. More news on: Fortress Biotech, Inc., Prana Biotechnology Ltd, VistaGen Therapeutics, Inc., Stocks on the move, , Read more ...

VTGN - AV-101 Stimulates the Formation of New Brain Cells in Nonclinical Studies

SOUTH SAN FRANCISCO, Calif., Jan. 31, 2019 (GLOBE NEWSWIRE) -- VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and disorders with high unmet need, today announced data from nonclin...
Previous 10 Next 10